

Condensed Consolidated Interim Financial Statements

Three and six months ended March 31, 2021 and 2020

(Unaudited – prepared by management) (expressed in thousands of Canadian dollars)

# NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, the financial statements must be accompanied by a notice indicating that they have not been reviewed by an auditor.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by CPA (Chartered Professional Accountants) Canada for a review of interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Loss

### For the three and six months ended March 31, 2021 and 2020

(Unaudited, expressed in thousands of Canadian dollars, except per share data)

		Three months ended		Six m	onths ended
		March 31, 2021 \$	March 31, 2020 \$	March 31, 2021 \$	March 31, 2020 \$
Revenues	14	4,686	7,492	12,219	16,101
Direct costs	_	(4,208)	(5,629)	(10,043)	(11,042)
	_	478	1,863	2,176	5,059
Expenses General and administration Sales and marketing Research and development Stock-based compensation Amortization of intangible assets Other income Foreign exchange loss (gain) Restructuring costs Finance (income) expense, net  Loss before income taxes	12(d) 16 17 –	1,214 1,304 463 185 59 (483) 52 691 (3) 3,482	1,558 1,796 481 374 62 - (338) - (26) 3,907	2,340 2,825 1,032 439 122 (808) 279 691 1 6,921	3,316 3,739 1,016 842 124 (293) (60) 8,684
Income tax (recovery) expense Current Deferred	_	(70) (648)	(305) 111	(460) (628)	(294) (55)
Net loss for the period	_	(2,286)	(1,850)	(3,657)	(3,276)
Basic and diluted loss per share		(0.02)	(0.02)	(0.03)	(0.03)
Weighted average number of shares outstanding – basic and diluted		111,600,354	111,244,530	111,525,349	111,105,412

Condensed Consolidated Interim Statements of Comprehensive Loss

### For the three and six months ended March 31, 2021 and 2020

(Unaudited, expressed in thousands of Canadian dollars)

	Three months ended		Six months ende	
	March 31, 2021 \$	March 31, 2020 \$	March 31, 2021 \$	March 31, 2020 \$
Net loss for the period	(2,286)	(1,850)	(3,657)	(3,276)
Other comprehensive loss				
Items that may be subsequently reclassified to profit or loss Foreign exchange translation (loss) gain	(41)	789	(357)	616
Total comprehensive loss for the period	(2,327)	(1,061)	(4,014)	(2,660)

Condensed Consolidated Interim Statements of Financial Position

### As at March 31, 2021 and September 30, 2020

(Unaudited, expressed in thousands of Canadian dollars)

	Note	March 31, 2021 \$	September 30, 2020 \$
Assets		•	•
Current assets Cash and cash equivalents Restricted cash Trade receivables Due from customers on contract Loans receivable, current Inventory Prepaids and other receivables Income taxes receivable	4 7 6 5	15,153 250 2,138 57 539 6,501 624 974	14,712 250 10,992 356 - 7,117 692 742 34,861
Non-current assets Loans receivable, non-current Deposits and other receivables Plant and equipment Right-of-use assets Intangible assets Deferred income tax asset	7	232 90 4,420 1,736 226 361	161 3,993 1,301 347
Total assets		7,065 33,301	5,802 40,663
Liabilities Current liabilities Borrowings Trade and other payables Customer deposits and deferred revenue Current portion lease liabilities Current portion of other liabilities	8 9 4 10 11(a)	2 3,929 2,189 714 127 6,961	667 7,704 1,771 427 124 10,693
Non-current liabilities Borrowings Deferred income tax liability Long-term portion of lease liabilities Long-term portion of other liability	8 10 11(a)	185 - 1,215 66 1,466	200 268 1,019 132 1,619
Total liabilities		8,427	12,312
Equity			
Share capital Warrants Contributed surplus Foreign currency translation reserve Deficit	12(b) 12(c)	80,093 1,040 10,060 418 (66,737)	79,840 1,641 9,151 775 (63,056)
Total equity		24,874	28,351
Total liabilities and equity	4.4	33,301	40,663
Contingencies and commitments	11		

Condensed Consolidated Interim Statements of Changes in Equity

### For the six months ended March 31, 2021 and 2020

(Unaudited, expressed in thousands of Canadian dollars)

	Share cap	oital					
	Number	Value \$	Warrants \$	Contributed surplus \$	Foreign currency translation reserve \$	Deficit \$	Total equity \$
Balance – September 30, 2019 Impact of adopting IFRS 16 Net loss for the period Effects of foreign currency translation Share issuance costs Shares issued on exercise of Underwriter's Warrants Shares issued on exercise of warrants Expiry of Underwriter's Warrants Shares issued on exercise of stock options Shares issued with restricted share rights Restricted share rights Stock-based compensation	110,836,515 - - - 54,446 145,794 - 183,000 190,000	79,063 - - 2 70 235 - 269 165	1,715 - - - (13) (59) (2) - -	8,035 - - - - - 2 (68) (165) 160 682	694 - - 616 - - - - - -	(58,563) (52) (3,276) - - - - - -	30,944 (52) (3,276) 616 2 57 176 - 201 - 160 682
Balance – March 31, 2020	111,409,755	79,804	1,641	8,646	1,310	(61,891)	29,510
Balance – September 30, 2020 Net loss for the period Effects of foreign currency translation Expiry of warrants Shares repurchased and cancelled (note 12b) Shares issued on exercise of stock options Shares issued with restricted share rights Restricted share rights Stock-based compensation	111,409,755 - - (40,000) 160,000 60,000	79,840 - - (29) 199 83 -	1,641 - - (601) - - - -	9,151 - - 601 - (48) (83) 168 271	775 - (357) - - - - -	(63,056) (3,657) - - (24) - - -	28,351 (3,657) (357) - (53) 151 - 168 271
Balance – March 31, 2021	111,589,755	80,093	1,040	10,060	418	(66,737)	24,874

Condensed Consolidated Interim Statements of Cash Flows

### For the six months ended March 31, 2021 and 2020

(Unaudited, expressed in thousands of Canadian dollars)

		Six months end	•
	Note	2021 \$	2020 \$
Cash flows generated from (used in) operating activities		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	()
Net loss for the period Items not affecting cash		(3,657)	(3,276)
Depreciation and amortization Gain on disposal of assets		1,264 10	766 (3)
Stock-based compensation	12(d)	439	842
Finance expense (income), net		1 (4.000)	(60)
Income tax recovery Inventory write-offs		(1,088) 213	(349) 83
Foreign exchange loss		279	(293)
Changes in non-cash working capital		(2,539)	(2,290)
Trade receivables		8,500	7,236
Prepaids and other receivables Loans receivable		8 (461)	(8)
Inventory		(461) (775)	(6,245)
Trade and other payables		(2,782)	(2,954)
Due from customers on contract and deferred revenue  Net cash generated from (used in) operating activities before		833	872
income taxes		2,784	(3,389)
Income taxes (paid)/received		180	(155)
Net cash generated from (used in) operating activities		2,964	(3,544)
Cash flows used in investing activities		// <b>=</b> >	(===)
Acquisition of plant and equipment Proceeds from disposal of plant and equipment		(1,562) 62	(550) 7
Acquisition of intangible assets		(2)	, -
Finance income received		72	148
Net cash used in investing activities		(1,430)	(395)
Cash flows (used in) generated from financing activities			
Share issuance costs Proceeds from exercise of stock options	12(4)	- 151	2 201
Proceeds from exercise of stock options  Proceeds from exercise of warrants	12(d) 12(c)	-	233
Repurchase of shares for cancellation	12(b)	(53)	-
(Repayment) proceeds from line of credit	10	(642) (294)	665 (195)
Payment of lease principal liabilities Payment of lease interest	10	(294) (74)	(62)
Payment received from finance leases		<b>`15</b> ´	5
Payment of other liability	11(a)	(26)	(68)
Net cash (used in) generated from financing activities		(923)	781
Effect of foreign exchange translation on cash		(170)	48
Increase (decrease) in cash and cash equivalents		441	(3,110)
Cash and cash equivalents - Beginning of period		14,712	18,665
Cash and cash equivalents - End of period		15,153	15,555
Non-cash transactions Acquisition of plant and equipment through accounts payable Purchase of inventory through accounts payable		(133) (580)	(104) -

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### 1 Nature of operations

EnWave Corporation ("EnWave" or "the Company") was incorporated under the Canada Business Corporations Act on July 14, 1999. The Company's principal business is the licensing of its intellectual property through royalty-bearing agreements and the design, construction, marketing and sales of vacuum-microwave dehydration machinery for the food, cannabis and biomaterial industries.

The registered office of the Company is 1000 Cathedral Place - 925 West Georgia Street, Vancouver, BC V6C 3L2, Canada.

The Company's wholly owned subsidiary, NutraDried Food Company, LLC ("NutraDried"), is a Limited Liability Corporation registered in Washington State. NutraDried manufactures, markets and sells certain dehydrated food products manufactured using EnWave's proprietary technology under the Company's Moon Cheese® trademark.

The Company's wholly owned subsidiary, REV Technology Corporation, is an incorporated subsidiary registered in the State of Delaware.

#### 2 Basis of preparation

#### Statement of compliance

These condensed consolidated interim financial statements ("interim financial statements") have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") as applicable to the preparation of interim financial statements, as set out in International Accounting Standard ("IAS") 34, Interim Financial Reporting. They do not include all the information required for a complete set of IFRS financial statements and should be read in conjunction with the audited annual consolidated financial statements of the Company for the year ended September 30, 2020. There are selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the last annual consolidated financial statements as at and for the year ended September 30, 2020.

These interim financial statements were approved for issuance by the Board of Directors for issue on May 26, 2021.

#### **Critical accounting estimates**

The preparation of consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. The Company regularly reviews its estimates and assumptions; however, it is possible that circumstances may arise which may cause actual results to differ from management estimates, and these differences could be material. Estimates and underlying assumptions are reviewed on an ongoing basis, and revisions to estimates are recorded prospectively.

#### Revenue recognition

The revenue recognition policy for customized equipment sales contracts is the percentage-of-completion method. The stage of completion is measured by reference to the actual contract costs incurred as a percentage of total estimated costs for each contract. Determining the estimated contract cost is considered a significant

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

accounting estimate which requires detailed knowledge of the costs to be incurred based on the required design customizations. If the total actual contract costs were to differ by 10% from management's estimated contract costs, the amount of revenue recognized in the period would be increased or decreased by \$361 (2020 - \$607).

#### Impairment of inventory

The Company measures inventory at the lower of cost and net realizable value, and in the event the net realizable value exceeds cost, an impairment charge is recorded. This determination requires judgement, which includes, among other factors, the selling price, less the estimated costs of completion and selling expenses.

#### Leases

The right-of-use asset and lease liability valuations are based on the present value of the lease payments over the lease term. The lease term is determined as the non-cancellable term of the lease, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. The Company applies judgement in evaluating whether it is reasonably certain whether or not to exercise the option to extend or terminate the lease, and any modifications to the lease term will result in the revaluation of the lease. The present value of the lease payments is dependent on the incremental borrowing rate used, to which the Company applies judgement in determining the rates.

#### Estimated useful lives of property, plant and equipment

Depreciation of property, plant and equipment is dependent upon estimates of useful lives and residual values which are determined through knowledge of the business and judgement. Residual values, useful lives and depreciation methods are reviewed annually for relevancy and changes are accounted for prospectively. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic conditions, market conditions and the useful lives of the assets.

#### Impairment of non-financial assets

At each reporting date, the Company assesses its non-financial assets to determine whether there are any indications of impairment. If any indication of impairment exists, an estimate of the asset's recoverable amount is calculated. Non-financial assets that do not generate independent cash flows are grouped together into a cash generating unit ("CGU"), which represents the lowest level at which largely independent cash flows are generated. The recoverable amount of a CGU is the greater of its value in use and its fair value less costs of disposal. Value in use is calculated as the present value of the estimated future cash flows discounted at appropriate discount rates. These calculations require the use of estimates and assumptions.

#### Warranty provision

The Company recognizes revenue from the sale of machines to customers. Machines are sold with a manufacturer's warranty valid for a fixed period not exceeding one year. The Company estimates, based on past experience with similar sales, that the warranty costs will not exceed 1% of revenues. The Company therefore recognizes a provision for warranty equal to 1% of revenue recognized.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

Share-based compensation

The fair value of stock options and warrants is calculated using the Black-Scholes option pricing model. When determining the fair value of stock options and warrants, management is required to make assumptions and estimates related to expected lives, volatility, risk-free rate, future dividend yields and estimated forfeitures at the initial grant date. Changes in assumptions used to estimate the fair value could result in materially different results.

#### 3 Significant accounting policies

The accounting policies adopted are consistent with the September 30, 2020 annual consolidated financial statements and the unaudited condensed consolidated interim financial statements should be read in conjunction with the Company's 2020 annual audited consolidated financial statements.

#### Accounting standards and amendments issued and not yet adopted

IAS 1 - Classification of Liabilities as Current or Non-Current

The amendment clarifies the classification requirements to determine if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing of recognition. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied retrospectively, with earlier application permitted. The Company is currently evaluating the potential impact of these amendments on the Company's consolidated financial statements.

#### 4 Contract assets and contract liabilities

Due from customers on contract consists of unbilled amounts typically resulting from sales under equipment purchase contracts when the cost-to-cost method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. The Company receives payments from customers based on a billing schedule, as established in the contracts. Accounts receivable are recognized when the right to consideration becomes unconditional.

Customer deposits and deferred revenue consists of advance payments and billings in excess of revenue recognized and deferred revenue. Contract liabilities are recognized as revenue when the Company performs under the contract.

Net contract assets (contract liabilities) consisted of the following:

	March 31, 2021 \$	September 30, 2020 \$
Due from customers on contract Customer deposits and deferred revenues	57 (2,189) (2,132)	356 (1,771) (1,415)

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

During the six months ended March 31, 2021, the Company recognized revenue from equipment sales and construction contracts of \$1,067 (2020 - \$1,286) that was included as deferred revenue at the beginning of the period.

### 5 Prepaids and other receivables

	March 31, 2021 \$	September 30, 2020 \$
Prepaid expenses	545	652
Indirect tax receivable	46	13
Other receivables	33	27
	624	692

#### 6 Inventory

	March 31, 2021 \$	September 30, 2020 \$
Machine parts and work-in-progress	3,159	2,939
Food products	2,989	3,736
Packaging supplies	353	442
	6,501	7,117

During the six months ended March 31, 2021, the Company recorded \$213 (2020 - \$83) of inventory write-offs related to food products, machine parts and packaging supplies. This was recognized as an expense and included in direct costs in the condensed consolidated interim statement of loss.

#### 7 Loans receivable

	March 31, 2021 \$	September 30, 2020 \$
Current	539	-
Non-current	232	-
	771	-

During the six months ended March 31, 2021, the Company recorded equipment finance loans of \$771 (September 30, 2020 - \$nil) to be paid by customers related to equipment purchase contracts. The loans receivable bear interest at annual interest rates ranging between 8% and 12%, have fixed terms ranging from 12 to 46 months and are amortized with monthly blended payments of interest and principal. The loans receivable are measured at amortized cost using the effective interest method and are secured by the underlying equipment purchased by the customer.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

### 8 Borrowings

	March 31, 2021 \$	September 30, 2020 \$
Line of credit (i)	-	667
Economic Injury Disaster Loan (ii)	187	200
Total borrowings	187	867
Current (i)	2	667
Non-Current (ii)	185	200
Total borrowings	187	867

- i) The Company's subsidiary, NutraDried, has a credit line agreement for up to US\$500 of short-term borrowings that is payable on demand. The credit facility bears interest rate at the Wall Street Journal Prime Rate plus 1.5%, with a floor of 4.25%. The amount outstanding at March 31, 2021 is \$nil (September 30, 2020 \$667). NutraDried is subject to current ratio and leverage ratio covenants under the terms of the credit facility and is in compliance with those covenants.
- ii) On June 15, 2020, NutraDried received proceeds from an Economic Injury Disaster Loan ("EIDL") with the U.S. Small Business Administration of US\$150. The loan is amortized over 30 years and accrues interest at the rate of 3.75% annually. The Company will commence making monthly installment payments consisting of principal and interest 12 months from the date of loan issuance. The EIDL loan is secured by all tangible and intangible personal property, including, but not limited to, inventory and equipment.

#### 9 Trade and other payables

	March 31, 2021 \$	September 30, 2020 \$
Trade payables Accrued liabilities	2,178 658	1,725 4,500
Personnel related accruals	835	1,238
Provision for warranty	258	241
	3,929	7,704

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### 10 Lease liabilities

The following is a continuity schedule of lease liabilities for the six months ended March 31, 2021 and 2020:

	Six months ended March 31,	
	2021 \$	2020 \$
Balance, October 1 Lease additions	1,446 835	1,622
Lease payments Interest expense on lease liabilities	(368) 74	(257) 62
Changes due to foreign exchange rates Balance, March 31	(58) 1,929	7 1,434
		.,
Current	714	423
Non-current	1,215	1,011
	1,929	1,434
Maturity of contractual undiscounted lease payments		March 31, 2021 \$
Less than one year		825
One to five years		1,294
		2,119

### 11 Contingencies and commitments

#### a) Other liability

On December 6, 2010, the Company entered into an Asset Purchase Agreement (the "INAP APA") to acquire the patents and know-how for the MIVAP vacuum microwave dehydration technology. On March 28, 2018, the Company renewed its INAP License for the exclusive worldwide rights to the know-how related to the MIVAP Vacuum microwave technology and agreed to pay minimum annual royalties. The agreements with INAP cover the US, Canadian and worldwide rights. Pursuant to the INAP APA and INAP License, the Company agreed to pay a portion of the license or royalty fees collected from the Company's customers who purchase EnWave equipment that makes use of the acquired patents and know-how. For usage in North America, the Company remits 25% for food applications and 12.5% for non-food applications, and the agreement expired on February 3, 2019. For usage outside of North America, the Company remits 25% for food applications and 12.5% for non-food applications, and the agreement expires on October 15, 2022. Additionally, the Company agreed to pay INAP a fee equal to 2.5% of the net purchase price of each machine sold that makes use of the acquired patents and know-how.

The acquired intangible asset was recorded at the fair value of the estimated minimum royalty amounts and subsequently at each reporting date at amortized cost. As at March 31, 2021, there was a minimum royalty obligation payable by the Company recorded in other liability of \$193 (September 30, 2020 - \$256).

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

	Undiscounted royalties payable US\$	Undiscounted royalties payable CA\$
2021	50	63
2022	100	125
2023	4	5
Total	154	193

#### b) Commitments payable to vendors by the Company

The Company has entered into various lease agreements for the rental of office space, plant facilities, and laboratory facilities. From October 1, 2019, the Company has recognized right-of-use assets for these leases, except for short-term and low-value leases. Short-term leases are leases with a lease term of 12 months or less and low-value assets comprise office and manufacturing equipment.

	March 31, 2021 \$	September 30, 2020 \$
Less than 1 year	18	62
Between 1 and 5 years	15	27
More than 5 years		<u>-</u>
Total	33	89

The Company is committed to incurring capital expenditures relating to the completion of the toll manufacturing facility of \$542 (September 30, 2020 - \$nil). These commitments are expected to be settled within the year.

#### c) Letter of credit to customers

As at March 31, 2021, the Company had a letter of credit for US\$810 (CA\$1,019) issued in favour of a customer related to the terms of an equipment purchase contract. The letter of credit is guaranteed by an Export Development Canada ("EDC") guarantee and is not subject to any other collateral requirements by the Company. The letter of credit will be returned to the Company upon confirmation that the equipment has been shipped to the customer according to the equipment purchase contract terms.

#### 12 Share capital

a) Authorized: unlimited number of voting common shares without par value. Issued and outstanding: 111,589,755.

Authorized: unlimited number of voting preferred shares, issuable in series. Issued and outstanding: nil.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### b) Issued and fully paid:

		Share capital
	Number	Value \$
Balance – October 1, 2019	110,836,515	79,063
Share issue costs Shares issued on exercise of Underwriter's Warrants Shares issued on exercise of Investor's Warrants Shares issued on exercise of stock options Shares issued on vesting of restricted share rights	54,446 145,794 183,000 190,000	2 70 235 269 201
Balance – September 30, 2020	111,409,755	79,840
Shares issued on exercise of stock options Shares issued on vesting of restricted share rights Shares repurchased and cancelled (i)	160,000 60,000 (40,000)	199 83 (29)
Balance - March 31, 2021	111,589,755	80,093

i) On October 19, 2020, the TSX Venture Exchange ("TSXV") accepted the Company's notice of intention to commence a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Company may repurchase up to 10,918,104 common shares, representing approximately 10% of the public float as of October 19, 2020, but no more than 2,228,195 in any 30-day period. The NCIB period commenced on October 22, 2020 and will end on the earlier of October 21, 2021, and the completion of purchases under the NCIB. All repurchased shares will be cancelled. During the six month period ended March 31, 2021, the Company purchased and cancelled 40,000 common shares for a total of \$53 (2020 - \$nil) at a volume weighted average price of \$1.32 per common share. The total cost of \$53 reduces share capital by \$29 (2020 - \$nil) and increases the deficit by \$24 (2020 - \$nil).

#### c) Warrants

The continuity of share purchase warrants during the six months ended March 31, 2021 and 2020 is as follows:

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

	Number of warrants	Weighted average exercise price \$	Fair value at grant date \$
Balance - September 30, 2019	7,953,731	1.39	0.26
Issued:     Investor's Warrants (i)  Exercised:     Underwriter's Warrants (ii)     Investor's Warrants (iii)  Expired:     Underwriter's Warrants (ii)	27,220 (54,446) (145,794) (6,509)	1.50 1.05 1.20 1.05	0.27 0.36 0.24 0.36
Balance - September 30, 2020	7,774,202	1.40	0.26
Expired: Investor's Warrants (iii)	(2,762,000)	1.20	0.24
Balance - March 31, 2021	5,012,202	1.50	0.27

- ii) Each Investor Warrant issued is exercisable into one common share of the Company at an exercise price of \$1.50 per share expiring on November 15, 2022. The fair value of the warrants at the date of grant was estimated at \$0.27 per warrant using the Black-Scholes model based on the following assumptions: Stock price volatility 39%, risk-free interest rate 1.63%, dividend yield 0%, and expected life of 5.0 years.
- iii) Each Underwriter's Warrant entitles the holder to purchase one common share and one-half of a share purchase warrant at an exercise price of \$1.05 and expired on November 15, 2019. The share purchase warrants issued on exercise are exercisable into one common share of the Company at an exercise price of \$1.50 per share expiring on November 15, 2022. The fair value of the Underwriter's Warrants was calculated using the Black-Scholes model to be \$0.36 per each Underwriter's Warrant. The following assumptions were used in estimating the fair value of the Underwriter's Warrants: Stock price volatility 42%, risk-free interest rate 1.44%, dividend yield 0%, and expected life of 2.0 years.
- iv) Each Investor Warrant issued is exercisable into one common share of the Company at an exercise price of \$1.20 per share expiring on October 22, 2020. The fair value of the warrants at the date of grant was estimated at \$0.24 per warrant using the Black-Scholes model based on the following assumptions: Stock price volatility 54%, risk-free interest rate of 0.81%, dividend yield 0%, and expected life of 5.0 years.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

The following table summarizes the warrants that remain outstanding as at March 31, 2021:

Exercise price \$	Number of warrants	Expiry date
1.50	5,012,202	November 15, 2022
	5,012,202	

#### d) Stock options

The Company's stock option plan (the "Option Plan") is available to eligible persons, whereby up to 10% of the issued common shares of the Company may be reserved for issuance under the Option Plan. The aggregate number of common shares reserved for issuance to any person within any one year may not exceed 5% of the number of outstanding common shares, on a non-diluted basis.

The exercise price of the options will be determined by the Board of Directors at the time of grant of the options, such price not to be less than the last daily closing price of the Company's common shares prior to the date of grant, less the discount permitted by the policies of the TSX Venture Exchange.

Options issued under the Option Plan will vest according to the terms approved by the Board of Directors for each specific grant, except for options granted to individuals engaged in investor relations activities, which must vest over a 12-month period according to the Option Plan.

The changes in options for the six months ended March 31, 2021 and 2020 were as follows:

	March 31, 2021		March 31, 2020		
	Number of	Weighted average exercise price	Number of	Weighted average exercise price	
	options	\$	options	\$	
Outstanding, beginning of the period	6,975,667	1.46	5,952,000	1.45	
Options granted	392,000	1.38	860,000	1.63	
Options exercised	(160,000)	0.94	(183,000)	1.10	
Options expired	(208,667)	1.33	(356,666)	1.50	
Outstanding, end of the period	6,999,000	1.47	6,272,334	1.48	
Exercisable, end of the period	5,660,334	1.50	4,191,916	1.30	

The weighted average fair value of options granted during the six months ended March 31, 2021 was \$0.60 per option (2020 - \$0.54).

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

The following weighted average assumptions were used in calculating the fair value of the stock options granted using the Black-Scholes model for the six months ended March 31, 2021 and 2020:

	Six months ended March 3 2021 20		
Risk-free interest rate	0.39%	1.51%	
Expected life	3.02 years	3.65 years	
Estimated volatility	60%	42%	
Forfeiture rate	1.25%	1.25%	
Dividend rate	0.00%	0.00%	

Stock options outstanding as at March 31, 2021 have the following expiry date and exercise prices:

Year of expiry	Exercise price per share \$	Number of options
2021 2022 2023 2024 2025 2026	0.94 - 1.28 1.00 - 1.09 1.07 - 1.45 1.37 - 2.19 1.06 - 1.25 1.47 - 1.65	260,000 432,400 2,481,267 2,150,000 1,433,333 242,000 6,999,000

During the six months ended March 31, 2021, the Company recorded stock-based compensation expense of \$439 (2020 - \$842), which includes compensation expense for stock options and for restricted share rights ("RSRs"). The fair value of each option and RSR is accounted for in the condensed consolidated interim statement of loss over the vesting period, and the related credit is included in contributed surplus.

#### e) Restricted share rights

On February 11, 2020, the shareholders of the Company approved the amendment to the RSR Plan pursuant to which the Company reserved up to a maximum of 1,895,000 common shares for RSRs. The common shares reserved under the RSR Plan, together with stock options outstanding under the Option Plan, cannot exceed, in aggregate, 10% of the issued and outstanding shares of the Company.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

The changes in RSRs for the six months ended March 31, 2021 and 2020 were as follows:

	March 31, 2021		March 31, 202	
	Number of RSRs	Weighted average grant date fair value \$	Number of RSRs	Weighted average grant date fair value \$
Outstanding, beginning of period	790,000	1.15	775,000	1.29
RSRs granted RSRS vested	95,000 (60,000)	1.32 1.38	20,000 (190,000)	1.11 1.06
RSRs forfeited	(5,000)	1.34	(80,000)	1.40
Outstanding, end of period	820,000	1.16	525,000	1.35

During the six months ended March 31, 2021, stock-based compensation expense of \$168 (2020 - \$160) was recorded for the RSRs vested during the period. RSRs vest three years from the award date, in accordance with the RSR Plan.

#### 13 Related party transactions

a) Key management personnel compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company and/or its subsidiaries, including any external director of the Company and/or its subsidiaries.

Remuneration of key management personnel of the Company during the three and six months ended March 31, 2021 and 2020 comprises the following expenses:

	Three months ended March 31,			ths ended March 31,
	2021 \$	2020 \$	2021 \$	2020 \$
Salaries, bonuses, and short-term				
employee benefits	467	236	1,072	991
Stock-based compensation	88	168	185	410
·	555	404	1,257	1,401

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### b) Transactions with related parties

The Company had transactions with related parties for the three and six months ended March 31, 2021 and 2020 in the normal course of business as shown in the table below:

	Three mor	Three months ended March 31,		ths ended March 31,
	2021 \$	2020 \$	2021 \$	2020 \$
Directors' fees	50	50	100	90
Stock-based compensation	51	111	128	185
	101	161	228	275

#### 14 Revenues

a) Revenue breakdown for the three and six months ended March 31, 2021 and 2020 is as follows:

_	Three months ended March 31,			
	2021 \$	2020 \$	2021 \$	2020 \$
Product sales, net	2,337	5,323	7,194	9,377
Equipment construction contracts	1,518	1,459	2,612	4,296
Equipment sales	451	455	1,435	1,236
Equipment rental fees, testing fees and other	217	110	495	645
Royalties and licensing fees	163	145	483	547
<u> </u>	4,686	7,492	12,219	16,101

Individual customers representing over 10% of the total revenue during the six months ended March 31, 2021 and 2020 were as follows:

	Marc	h 31, 2021	March 31, 2020		
Customer	\$	%	\$	%	
A	2,213	18	2,491	15	
Others	10,006	82	13,610	85	
	12,219	100	16,101	100	

b) Trade receivables from customers representing more than 10% of the total amount were as follows:

	Marc	h 31, 2021	September 30, 2020	
Customer	\$	%	\$	%
Χ	408	19	7,392	67
Υ	-	-	1,059	10
Others	1,730	81	2,541	23
	2,138	100	10,992	100

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### 15 Expenses by nature

Details of consolidated expenses by nature for direct costs, general and administration, sales and marketing, and research and development expenses for the three and six months ended March 31, 2021 and 2020 are shown below:

-	Three mo	onths ended March 31,	Six months ended March 31,		
Details of expenses by nature	2021 \$	2020 \$	2021 \$	2020 \$	
Cost of materials	3,141	3,895	7,734	7,197	
Salaries, wages and employee expenses	2,202	2.996	4.644	6,517	
Commissions, travel and promotional costs	653	1,211	1,454	2,558	
Depreciation of plant and equipment	535	345	1,142	642	
Professional services	415	488	826	1,206	
Other expenses	82	158	147	342	
Office and courier	82	119	148	299	
Facility expenses	73	109	139	209	
Bad debt	6	143	6	143	
Total expenses	7,189	9,464	16,240	19,113	

#### 16 Government assistance

EnWave received COVID-19 financial relief in Canada under the Canada Emergency Wage Subsidy ("CEWS") and the Canada Emergency Rent Subsidy ("CERS") programs. The CEWS program is a wage subsidy program launched by the Canadian federal government to qualifying employers to subsidize payroll costs during the COVID-19 pandemic. The CERS program provides commercial rent and mortgage support to eligible businesses affected by COVID-19. The qualified subsidy amounts received under the programs are non-repayable. The amount of subsidy recognized from the Canadian federal government under the programs for the six months ended March 31, 2021 was \$808 (2020 - \$nil) and has been recorded as other income on the consolidated statement of loss.

#### 17 Restructuring costs

On February 18, 2021, the Company completed a restructuring at NutraDried. As part of the NutraDried restructuring, the Company reduced its executive, administrative and production staffing by 24 positions, which resulted in severance and restructuring charges of \$691 during the period. Additionally, the Company reduced or eliminated the use of certain third-party consultants and contractors.

#### 18 Financial instruments risk

The use of financial instruments exposes the Company to a number of risks. These risks include credit risk, liquidity risk, and market risk. The Company has established policies and procedures to manage these risks, with the objective of minimizing the adverse effects that changes in the variable factors underlying these risks could have on the Company's interim financial statements.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### Credit risk

Credit risk is the risk that a counterparty will not meet its obligation under a financial instrument or customer contract, leading to a financial loss being incurred by the Company. Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents, restricted cash, trade receivables, due from customers on contract and loans receivable. The Company mitigates its exposure to credit loss by maintaining the majority of cash balances with major Canadian financial institutions.

The Company provides credit to its customers in the normal course of business and, as such, has exposure to credit risk in relation to the collection of trade receivables, due from customers on contract and loans receivable. Prior to issuing credit, management reviews the customer, taking into account its financial position, historical experience, and other factors. The Company minimizes its credit risk associated with trade receivables and due from customers on contract by maintaining ongoing close contact with customers, by requiring commercial letters of credit, by reviewing individual account balances, and by proactively following up on overdue amounts. The Company maintains a provision for credit losses relating to specific losses estimated on individual exposures. As at March 31, 2021, the Company has recorded a \$nil (2020 - \$64) provision for expected credit losses.

The Company is exposed to credit risk in trade receivables by way of concentration of credit with a small number of customers. The Company determines its concentration of credit risk if the balance is more than 10% of total revenue or trade receivables. The Company expects these customers to remain as large customers in the future. Significant change in these customer relationships could materially impact the Company's future financial results. The Company seeks and ordinarily obtains progress advances in respect of its construction contracts. The maximum exposure to loss arising from trade receivables and loan receivables are equal to their total carrying amounts.

The Company transacts with a number of Canadian and U.S. banks and other brokerages. Due to the creditworthiness of its counterparties, the Company regards all changes in fair value of foreign exchange derivatives as arising only from changes in market factors, including foreign exchange rates. The Company monitors the exposure to any single counterparty along with its financial position. If it is determined that a counterparty has become materially weaker, the Company will work to reduce its credit exposure to that counterparty.

The following table provides information regarding the aging of receivables as at March 31, 2021:

	Neither past due nor impaired	Past dı	ired	
	0 – 30 days	31 – 90 days	91 – 365 days	Over 365 days
Trade receivables	1,965	77	84	12
Due from customers on contract Loans receivable	57 771	-	-	-
	2,793	77	84	12

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due.

The Company manages liquidity risk through ongoing management and forecasting of cash flows, budgeting, and equity financings. Cash flow forecasting is performed to monitor cash requirements and to manage capital management decisions. Such forecasting takes into account current and potential customers, contractual obligations and the Company's technology development and commercialization expectations.

The Company's investment policy is to invest its cash in highly liquid short-term interest-bearing investments with varying maturities selected with regards to the expected timing of expenditures from continuing operations.

The Company attempts to ensure that sufficient funds are available to meet its operating requirements, after taking into account existing cash. The Company manages liquidity risk through the management of its capital structure and financial leverage. As at March 31, 2021, the Company had cash and cash equivalents of \$15,153 to settle current liabilities of \$6,961.

#### a) Financial assets maturity table:

	0 – 30 days	31 – 90 days	91- 365 days	Over 365 days
Cash and cash equivalents and restricted cash	15,153	-	250	-
Trade receivables	1,983	155	-	-
Due from customers on contract	57	-	-	-
Loans receivable	75	86	378	232
Income taxes receivable		-	974	
	17,268	241	1,602	232

#### b) Financial liabilities, excluding other liability, maturity table:

	0 – 30	31 – 90	91- 365	Over 365
	days	days	days	days
Borrowings	2	-	-	185
Trade and other payables	3,851	78	-	-
Lease liabilities	57	115	542	1,215
	3,910	193	542	1,400

#### Market risk

Market risk is the risk that the fair value of future cash flows of the Company will fluctuate due to changes in interest rates and foreign currency exchange rates.

#### Interest rate risk

Interest rate risk refers to the risk that the value of a financial instrument or cash flows associated with the instrument will fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk from the interest rate impact on cash and cash equivalents, restricted cash, and borrowings. The Company earns interest on deposits based on current market interest rates, which during the six months ended March 31, 2021

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

ranged from 0.40% to 2.10% (2020 - 2.05% to 2.10%). A 1% change in interest rates would affect the results of operations by approximately \$64 (2020 - \$70).

Foreign exchange risk

The Company is exposed to the following foreign exchange risks related to the fluctuation of foreign exchange rates:

- (i) the Company operates in the United States and a portion of its expenses are incurred in US dollars; and
- (ii) the Company is exposed to currency risk through customers with sales contracts denominated in US dollars.

A significant change in the currency exchange rate of the Canadian dollar relative to the US dollar could have an effect on the Company's results of operations. As at March 31, 2021, all of the Company's liquid assets and liabilities were held in Canadian dollars and US dollars.

The Company enters into foreign exchange derivative contracts when appropriate to minimize exposure to foreign currencies when appropriate. As at March 31, 2021, and September 30, 2020, the Company held no foreign exchange contracts. The fair values of the foreign exchange derivatives are recurring measurements and are determined whenever possible based on observable market data. If observable market data on the financial derivatives is not available, the Company uses observable spot and forward foreign exchange rates to estimate their fair values.

A change in the value of the Canadian dollar by 10% relative to foreign currencies the Company is exposed to would have affected the Company's net loss for the six months ended March 31, 2021 and 2020 as follows:

	2021	2020
Currency	\$	\$
US dollar	61	61

#### Capital management

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure, which optimizes the cost of capital at an acceptable risk.

In the management of capital, the Company includes the components of equity attributable to common shareholders. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue debt and acquire or dispose of assets. In order to facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions.

There were no changes in the Company's approach to capital management in the period. Neither the Company nor any of its subsidiaries are subject to externally imposed capital requirements.

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

### 19 Segmented information

The Company has assessed its operating segments to be EnWave and NutraDried according to the manner in which information is used by the Chief Operating Decision Maker (the "CODM"). The Company has determined that the Chief Executive Officer of the parent company is its CODM. The results of operations and the assets for each segment are shown below:

As at		March 31, 2021		Sep	tember 30, 2020	)
	EnWave \$	NutraDried \$	Total \$	EnWave \$	NutraDried \$	Total \$
Assets	·	·	·	·	·	·
Trade receivables Inventory Loan receivables	962 3,160 771	1,176 3,341	2,138 6,501 771	996 2,939	9,996 4,178	10,992 7,117
Plant and equipment	1,626	2,794	4,420	807	3,186	3,993
Right-of-use assets Intangible assets	855 214	881 12	1,736 226	1,018 327	283 20	1,301 347
	7,588	8,204	15,792	6,087	17,663	23,750
Liabilities						
Trade and other payables Customer deposits and deferred revenue	1,994 2,189	1,935	3,929 2,189	1,638 1,771	6,066	7,704 1,771
Borrowings	-	187	187	-	867	867
Lease liabilities Other liability	987 193	942	1,929 193	1,155 256	291 -	1,446 256
	5,363	3,064	8,427	4,820	7,224	12,044

For the six months ended	March 31, 2021				
	EnWave \$	NutraDried \$	Elimination adjustments	Total \$	
Revenues – external customers	5,024	7,195	-	12,219	
Revenues – other segments	790	-	(790)		
Total revenues	5,814	7,195	(790)	12,219	
Expenses	(6,605)	(11,041)	962	(16,684)	
Other income	808	-	-	808	
Net income (loss)	17	(3,846)	172	(3,657)	

For the six months ended	March 31, 2020				
	EnWave \$	NutraDried \$	Elimination adjustments \$	Total \$	
Revenues – external customers	6,724	9,377	-	16,101	
Revenues – other segments	770	-	(770)		
Total revenues	7,494	9,377	(770)	16,101	
Expenses	(9,418)	(10,597)	638	(19,377)	
Net loss	(1,924)	(1,220)	(132)	(3,276)	

Revenues for EnWave comprise all equipment sales and construction contracts, royalties and licensing fees, and equipment rental fees, testing fees and other referred to in note 14 and account for approximately 41% of the

Notes to the Condensed Consolidated Interim Financial Statements (Unaudited, expressed in thousands of Canadian dollars)

consolidated revenues. Revenues for NutraDried relate to product sales referred to in note 14 and account for approximately 59% of the consolidated revenues.